International Medical Center of Biomaterials Processing and Cryostorage MISX:GEMA Stock Report
Last Price
₽698.00
Market Cap
₽1.0b
7D
-2.2%
1Y
0.8%
Updated
18 May, 2022
Data
Company Financials
GEMA fundamental analysis
Snowflake Score
Valuation
3/6
Future Growth
0/6
Past Performance
5/6
Financial Health
5/6
Dividends
3/6
GEMA Stock Overview
International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company operates as a licensed bank for personal storage of cord blood stem cells in Russia and the CIS countries.
International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company operates as a licensed bank for personal storage of cord blood stem cells in Russia and the CIS countries. The company is based in Moscow, Russia. International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company is a subsidiary of Human Stem Cells Institute PJSC.
International Medical Center of Biomaterials Processing and Cryostorage Fundamentals Summary
How do International Medical Center of Biomaterials Processing and Cryostorage's earnings and revenue compare to its market cap?
Is International Medical Center of Biomaterials Processing and Cryostorage undervalued compared to its fair value and its price relative to the market?
Valuation Score
3/6
Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GEMA (RUB698) is trading below our estimate of fair value (RUB5904.17)
Significantly Below Fair Value: GEMA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: GEMA is good value based on its PE Ratio (7.6x) compared to the European Healthcare industry average (19.3x).
PE vs Market: GEMA is poor value based on its PE Ratio (7.6x) compared to the Russian market (6.9x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GEMA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GEMA is overvalued based on its PB Ratio (5.2x) compared to the XE Healthcare industry average (2x).
Future Growth
How is International Medical Center of Biomaterials Processing and Cryostorage forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
13.4%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as International Medical Center of Biomaterials Processing and Cryostorage has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has International Medical Center of Biomaterials Processing and Cryostorage performed over the past 5 years?
Past Performance Score
5/6
Past Performance Score 5/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
6.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GEMA has high quality earnings.
Growing Profit Margin: GEMA's current net profit margins (51.3%) are higher than last year (50.6%).
Past Earnings Growth Analysis
Earnings Trend: GEMA's earnings have grown by 6.7% per year over the past 5 years.
Accelerating Growth: GEMA's earnings growth over the past year (11.2%) exceeds its 5-year average (6.7% per year).
Earnings vs Industry: GEMA earnings growth over the past year (11.2%) underperformed the Healthcare industry 50.3%.
Return on Equity
High ROE: GEMA's Return on Equity (67.7%) is considered outstanding.
Financial Health
How is International Medical Center of Biomaterials Processing and Cryostorage's financial position?
Financial Health Score
5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: GEMA's short term assets (RUB590.5M) exceed its short term liabilities (RUB165.6M).
Long Term Liabilities: GEMA's short term assets (RUB590.5M) exceed its long term liabilities (RUB311.7M).
Debt to Equity History and Analysis
Debt Level: GEMA has more cash than its total debt.
Reducing Debt: GEMA's debt to equity ratio has increased from 0.01% to 14.9% over the past 5 years.
Debt Coverage: GEMA's debt is well covered by operating cash flow (810.6%).
Interest Coverage: GEMA earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is International Medical Center of Biomaterials Processing and Cryostorage current dividend yield, its reliability and sustainability?
Dividend Score
2/6
Dividend Score 2/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
12.39%
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: GEMA's dividend (12.39%) is higher than the bottom 25% of dividend payers in the Russian market (3.97%).
High Dividend: GEMA's dividend (12.39%) is in the top 25% of dividend payers in the Russian market (11.03%)
Stability and Growth of Payments
Stable Dividend: Too early to tell whether GEMA's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if GEMA's dividend payments are increasing as they only just started paying a dividend.
Earnings Payout to Shareholders
Earnings Coverage: With its high payout ratio (94.6%), GEMA's dividend payments are not well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (54.2%), GEMA's dividend payments are covered by cash flows.
How experienced are the management team and are they aligned to shareholders interests?
CEO
International Medical Center of Biomaterials Processing and Cryostorage has no CEO, or we have no data on them.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company's employee growth, exchange listings and data sources
Key Information
Name: International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company
International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company
P.1, Room 24, House 3, Building 1
Floor 1
Moscow
Moskovskaya obl.
119333
Russia
Listings
Company Analysis and Financial Data Status
All financial data provided by Standard & Poor's Capital IQ.
Data
Last Updated (UTC time)
Company Analysis
2022/05/18 00:00
End of Day Share Price
2022/05/18 00:00
Earnings
2021/12/31
Annual Earnings
2021/12/31
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.